Topical compositions containing fucoidan and galactan and their use in reducing skin thickness

By regulating the protein expression of skin cells through topical composition, the problem of weakened skin barrier function and increased proliferation in sensitive skin is solved, achieving the effects of reducing skin thickness and inhibiting cell proliferation.

CN123124960APending Publication Date: 2026-11-17CLARIANT (CANADA) INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202580026226.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-02-23
Filing Date
2025-02-20
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

There is a lack of effective compositions in the prior art to treat symptoms of sensitive skin, such as weakened skin barrier function, increased skin proliferation and increased skin thickness, which lead to burning and stinging sensations.

Method used

A topical composition is provided, comprising fucoidan and galactomannan and a specific proportion of preservatives, such as glycerol, caprylic acid glyceride, sodium benzoate, etc., for reducing skin thickness and inhibiting skin cell proliferation by regulating the expression of proteins such as Ki67, keratin 14, Clasp2 and Wnt5a in skin cells.

Benefits of technology

This composition can effectively reduce skin thickness, inhibit skin cell proliferation, regulate the expression of related proteins, and alleviate the symptoms of sensitive skin.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

A stable topical composition comprising fucoidan and galactan in a dry weight ratio of about 0.75:about 1 (w / w) to about 20:about 1 (w / w), water, a first preservative comprising at least 3% w / w glycerol and a second preservative comprising phenylpropanol; and its use for reducing epidermal thickness and / or inhibiting skin cell proliferation in subjects with such need.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application relates to topical compositions comprising fucoidan and galactan, and their use for reducing skin thickness. More specifically, this application relates to topical compositions comprising fucoidan and galactan, and containing certain preservatives, and their use for reducing skin thickness and / or inhibiting skin cell proliferation. Background Technology

[0002] Although the term "sensitive skin" is not clearly defined in the art, it is generally used to refer to skin with certain characteristics and symptoms, such as weakened skin barrier function, increased transdermal permeability (characterized by reduced loricrin expression in skin cells), increased skin proliferation, increased skin thickness, and hypersensitivity to external or internal triggers. Triggers can be environmental conditions such as wind, pollution, temperature changes, hard water, poor sanitation, cosmetics or care products, diet, or certain medications. Triggers may also be related to stress in the subject. Subjects with sensitive skin may experience burning and / or tingling sensations on their skin.

[0003] There is an urgent need for a composition that can treat at least some of the symptoms of sensitive skin.

[0004] This specification cites several references, the entire contents of which are incorporated herein by reference. Summary of the Invention

[0005] More specifically, the following items are provided according to this application.

[0006] Item 1. Use of a topical composition, wherein the topical composition comprises fucoidan and galactan in a dry weight ratio of about 0.75:about 1 (w / w) to about 20:about 1 (w / w), water, a preservative comprising at least 3% w / w glycerol, and another preservative comprising at least one of: (i) glyceryl caprylate, (ii) water (and) glycerol (and) sodium levulinate, (iii) another part of at least 15% w / w glycerol, and (iv) sodium benzoate; said topical composition is used to reduce epidermal thickness and / or inhibit skin cell proliferation in a subject with such need.

[0007] Project 2. As per the purpose of Project 1, for (i) reducing the expression of at least one of ki67, keratin 14 (K14), cytosolic connecton-associated protein 2 (Clasp2), and Wnt family member 5A (Wnt5a); and / or for (ii) increasing the expression of stylosin in the skin cells of a subject in need of this.

[0008] Project 3. As per the application of Project 2, the expression of at least two of ki67, K14, Clasp2 and Wnt5a in skin cells is reduced.

[0009] Item 4. According to the use of any one of Items 1-3, said composition comprises fucoidan and galactan in a dry weight ratio of about 12:about 1 (w / w) to about 18:about 1 (w / w).

[0010] Item 5. According to the use of any one of Items 1-3, wherein the fucoidan is extracted from brown algae, and / or the galactan is extracted from red algae.

[0011] Item 6. According to the use of any one of Items 1-3, wherein the fucoidan is extracted from *Cynodon dactylon*, and / or the galactan is extracted from *Asparagus chinensis*.

[0012] Item 7. According to the use of any one of Items 1-6, said other preservative comprises at least one of the following: glyceryl caprylate, water (and) glycerol (and) sodium levulinate, and sodium benzoate.

[0013] Item 8. According to the use of any one of Items 1-7, the topical composition further includes sorbitol.

[0014] Item 9. According to the use of any one of Items 1-8, the topical composition further comprises potassium sorbate.

[0015] Item 10. A topical composition comprising fucoidan and galactan in a dry weight ratio of about 0.75:about 1 (w / w) to about 20:about 1 (w / w), water, a preservative comprising at least 3% w / w glycerol, and another preservative comprising at least one of the following: (i) glyceryl caprylate, (ii) water (and) glycerol (and) sodium levulinate, (iii) another part of at least 15% w / w glycerol, and (iv) sodium benzoate.

[0016] Item 11. The composition according to Item 10, comprising fucoidan and galactan in a dry weight ratio of about 12:about 1 (w / w) to about 18:about 1 (w / w).

[0017] Item 12. The composition according to Item 10 or 11, wherein the fucoidan is extracted from brown algae, and / or the galactan is extracted from red algae.

[0018] Item 13. A composition according to any one of Items 10-12, wherein the fucoidan is extracted from *Leptochloa crus-galliculina*, and / or the galactan is extracted from *Asparagus chinensis*.

[0019] Item 14. A composition according to any one of Items 10-13, wherein the other preservative comprises at least one of the following: glyceryl caprylate, water (and) glycerol (and) sodium levulinate, and sodium benzoate.

[0020] Item 15. The composition according to any one of items 10-14 further comprises sorbitol and / or potassium sorbate.

[0021] Item 1. Use of a topical composition, wherein the topical composition comprises fucoidan and galactan in a dry weight ratio of about 0.75:about 1 (w / w) to about 20:about 1 (w / w), water, a first preservative comprising at least 3% w / w glycerol, and a second preservative comprising phenylpropanol; said topical composition is used to reduce epidermal thickness and / or inhibit skin cell proliferation in a subject with this need.

[0022] Item '2. According to the use of Item '1, the composition comprises fucoidan and galactan in a dry weight ratio of about 12:about 1 (w / w) to about 18:about 1 (w / w).

[0023] Item '3. As per the use of Item '1' or 2, wherein the fucoidan is extracted from brown algae, and / or the galactan is extracted from red algae.

[0024] Item 4. According to the use of any one of Items 1-3, wherein the fucoidan is extracted from *Cynodon dactylon*, and / or the galactan is extracted from *Asparagus spp.*

[0025] Item 5. According to the use of any one of Items 1-4, wherein the second preservative is composed of phenylpropanol.

[0026] Item 6. According to the use of any of Items 1-5, wherein the second preservative consists of about 0.2-0.4% w / w phenylpropanol.

[0027] Item 7. According to the use of any of Items 1-6, wherein the first preservative comprises or consists of about 14% w / w to about 65% w / w glycerol.

[0028] Item 8. According to the use of any one of Items 1-7, the first preservative comprises or consists of: about 20% w / w to about 60% w / w glycerol, or about 30% w / w to about 60% w / w glycerol, or about 40% w / w to about 60% w / w glycerol, or about 45% w / w to about 55% w / w glycerol, or about 50% w / w to about 53% w / w glycerol.

[0029] Item 9. A stable topical composition comprising fucoidan and galactan in a dry weight ratio of about 0.75:about 1 (w / w) to about 20:about 1 (w / w), water, a first preservative comprising about 14% w / w to about 65% w / w glycerol, and a second preservative comprising about 0.2-0.4% w / w phenylpropanol.

[0030] Item '10. The composition according to Item '9, comprising fucoidan and galactan in a dry weight ratio of about 12:about 1 (w / w) to about 18:about 1 (w / w).

[0031] Item '11. The composition according to Item '9 or 10, wherein the fucoidan is extracted from brown algae, and / or the galactan is extracted from red algae.

[0032] Item 12. A composition according to any one of Items 9-11, wherein the fucoidan is extracted from *Leptochloa crus-galliculina*, and / or the galactan is extracted from *Asparagus chinensis*.

[0033] Item 13. A composition according to any one of Items 9-12, wherein the second preservative is composed of phenylpropanol.

[0034] Item 14. A composition according to any one of Items 9-12, wherein the second preservative consists of about 0.2-0.4% w / w phenylpropanol.

[0035] Item 15. A composition according to any one of Items 9-14, wherein the first preservative comprises or consists of glycerol at about 14% w / w to about 65% w / w.

[0036] Item '16. The composition according to Item '15, wherein the first preservative comprises or consists of: about 20% w / w to about 60% w / w glycerol, or about 30% w / w to about 60% w / w glycerol, or about 40% w / w to about 60% w / w glycerol, or about 45% w / w to about 55% w / w glycerol, or about 50% w / w to about 53% w / w glycerol.

[0037] Item 17. The use of any of Items 1-8 or the composition of any of Items 9-16, wherein the galactomannan is present in the form of a syrup comprising galactomannan, glycerol and phenylpropanol.

[0038] Item '18. According to the use or composition of Item '17, said syrup comprises about 50% w / w (e.g., 50.225% w / w) of galactomannan, about 49% w / w (e.g., 49.475% w / w) of glycerol and about 0.3% w / w of phenylpropanol.

[0039] Item '19. The use or composition according to Item '18, wherein the composition comprises about 6.25% w / w galactomannan syrup and about 2.5% w / w fucoidan.

[0040] Item '20. A stable topical composition comprising the following components:

[0041] Project '21. Approximately 40.95% w / w of water;

[0042] Project '22. Approximately 6.25% w / w galactomannan syrup;

[0043] Project '23. Approximately 2.5% w / w fucoidan;

[0044] Project '24. Approximately 50% w / w glycerol; and

[0045] Project '25. Approximately 0.3% w / w phenylpropanol.

[0046] Item '26. The composition according to Item '20, wherein the galactomannan syrup comprises galactomannan, glycerol, and phenylpropanol.

[0047] Item '27. The composition according to Item '20 or 21, wherein the galactomannan syrup comprises about 50% w / w (e.g., 50.225% w / w) of galactomannan, about 49% w / w (e.g., 49.475% w / w) of glycerol and about 0.3% w / w of phenylpropanol.

[0048] Use of the composition defined in any one of items '28' or '20-22' for reducing epidermal thickness and / or inhibiting skin cell proliferation in subjects with such need.

[0049] In a specific embodiment, the subject requiring this is a human being.

[0050] Other objects, advantages, and features of this application will become more apparent upon reading the following non-limiting description of specific embodiments, which are given by way of example only and with reference to the accompanying drawings. Attached Figure Description

[0051] In the following figures:

[0052] Figure 1The effect of Aldavine™ 5X treatment on epidermal thickness is shown in the data where the skin substitute was untreated (black column), or treated with 1% or 2% Aldavine™ 5X (white column), or treated with 734 μM methotrexate (MTX, gray column) as a positive control. The data represent quantitative results of epidermal thickness, normalized to 100% with the untreated condition as 100%.

[0053] Figure 2 The effect of Aldavine™ 5X treatment on Ki67 expression is shown in the data for untreated skin substitutes (black column), or treated with 1% or 2% Aldavine™ 5X (white column), or treated with 734 μM methotrexate (MTX, gray column) as a positive control. The data represent quantitative results of Ki67 positive cells, normalized to 100% for untreated conditions.

[0054] Figure 3 The effect of Aldavine™ 5X treatment on K14 expression is shown, with skin substitutes untreated (black column), or treated with 1% or 2% Aldavine™ 5X (white column), or treated with 734 μM methotrexate (MTX, gray column) as a positive control. The data represent quantitative results of K14 intensity in relation to area, normalized to 100% for untreated conditions.

[0055] Figure 4 The effect of Aldavine™ 5X treatment on CLASP2 expression is shown, with skin substitutes untreated (black column), or treated with 1% or 2% Aldavine™ 5X (white column), or treated with 734 μM methotrexate (MTX, gray column) as a positive control. The figure represents the quantitative results of Clasp2 expression relative to total protein, normalized to 100% for untreated conditions.

[0056] Figure 5 The effect of Aldavine™ 5X treatment on Wnt5a expression is shown in the following figures: untreated skin substitute (black column), treated with 1% or 2% Aldavine™ 5X (white column), or treated with 734 μM methotrexate (MTX, gray column) as a positive control. The numbers represent the quantitative results of Wnt5a intensity in relation to area and are normalized to 100% with the untreated condition.

[0057] Figure 6The effect of Aldavine™ 5X treatment on pachyrhein expression is shown, with skin substitutes untreated (black column), or treated with 1% or 2% Aldavine™ 5X (white column), or treated with 734 μM methotrexate (MTX, gray column) as a positive control. The data represent quantitative results of pachyrhein intensity in relation to cell number, normalized to 100% for untreated conditions. Detailed Implementation

[0058] This application provides the use of a topical composition comprising fucoidan, galactomannan, and a preservative for reducing at least one of the following in subjects with need: skin cell proliferation, skin thickness, Ki67 expression in skin cells, K14 expression in skin cells, Clasp2 expression in skin cells, and Wnt5a expression in skin cells, and / or increasing the expression of scleroderma protein in skin cells. This application relates to the use of the topical composition for treating, preventing, or alleviating disorders and diseases associated with excessive skin cell proliferation and / or thickness.

[0059] The skin cells used in this article refer to at least one of fibroblasts and keratinocytes.

[0060] Fucoidan is a polysaccharide primarily derived from the cell walls of brown algae (Phaeophyceae), belonging to genera such as *Ascophyllum*, *Fucus*, *Pelvetia*, and *Himmanthaligenera*. These algae are also found in some marine animals, such as sea urchins and sea cucumbers. The sulfated form of fucoidan, extracted from the cell walls of brown algal branches, is called fucoidan sulfate ester. It is composed of heterogeneous molecules, mainly containing sulfated L-fucose polymers with an average molar mass between 5000 and 800,000 g / mol. This polymer also contains uronic acid. Although the degree of sulfation, molecular weight, and sugar residue structure of fucoidan vary by species, multiple studies have clearly shown that brown algal fucoidan (e.g., *Ascophyllum* fucoidan) contains a large number of α(1→3) and α(1→4) glycosidic bonds.

[0061] Galactan is another polysaccharide mainly derived from the cell walls of red algae (Rhodophyta). The most abundant galactans in red algae are carrageenan and agarose. This polysaccharide plays an important physiological role in resisting mechanical stress, hydration, and ion and osmotic regulation required in the marine environment. Crude galactan is extracted from the cell walls of red algal branches and is composed of heterogeneous molecules, mainly including sulfated β-D-galactose, xylose, and galactose polymers with an average molar mass between 50,000 and 800,000 g / mol.

[0062] Tables 1 and 2 summarize the methods for obtaining fucoidan and galactan from various species, respectively. Generally, brown algae are a good source of fucoidan, while red algae are a good source of galactan. [Table 1]: Red algae as sources of galactomannan and their known extraction methods [Table 2]: Red algae as sources of galactomannan and their known extraction methods

[0063] The term "fucose" as used in this article refers to a polysaccharide containing sulfated fucose and uronic acid. However, this does not include, but is not limited to, the following seaweeds: Laminariales, Chordariales, and Fucales, including Kjellmaniella crassifolia, Laminaria japonica, Kjellmaniella, Fucus, Nemacystus, Cladosiphonokamuranus, Undaria, Undaria pinnatifida, Wakame Mekabu, Ecklonia kurome, Stichopus japonicus, Eisenia, Ecklonia, Giant kelp, Lessonia nigrescence, Gelidium, Gracilaria, and Pteroclavia. The following species, including *capillacae*, *Sargassum* sp., *Padina gymnospora*, *Adenocystis utricularis*, *Pelvetia canaliculata*, *Chorda filum*, and *Pachyphyta*, as well as organisms derived from the phylum Echinodermata, sea cucumbers, sea urchins, and starfish, all contain fucoidan suitable for the uses and methods of this application. The fucoidan of this application is illustrated herein by example from the brown alga *Pachyphyta*.

[0064] As used in this article, the term "galactan" refers to a polysaccharide containing sulfated β-D-galactose, xylose, and uronic acid. However, this does not include, but is not limited to, the following seaweeds: Rhodomelaceae, Corallinaceae, Gracilariales, Ceramales, and Gigartinales, including *Asparagus maontanei*, *Bostrychia maontanei*, *Corallina* species, *Polysiphonia lanosa*, *Gracilaria* species, *Acanthophoraspicifer*, *Georgiella confluens*, *Laurencia coronopus*, *Porphyra haitanensis*, *Botryocladia occidentalis*, *Cryptopleura ramosa*, *Chondrus ascellatus*, *Gymnogongrus tolurus*, *Phacelocarpus peperocarpos*, and *Sargassum*. All of these contain galactomannans suitable for the uses and methods described in this application. The galactomannans described herein are exemplified by those derived from the red algae *Asparagus chinensis*.

[0065] Preparation of fucoidan

[0066] Fucoidan can be extracted and prepared from various algae using known methods, and the purified products and products containing fucoidan can be used in this application.

[0067] In one specific embodiment, the fucoidan of this application is obtained from *Tetracentron sinense*. In its natural state, fucoidan is composed of heterogeneous molecules, primarily containing high-molecular-weight sulfated L-fucose polymers bound to uronic acid. Furthermore, multiple studies have clearly demonstrated that *Tetracentron sinense* fucoidan contains a large number of α(1→3) and α(1→4) glycosidic bonds.

[0068] Natural fucoidan (i.e., naturally containing minerals)

[0069] Fresh, frozen, or dried clean algae can be made into a fine powder. It is preferred to chop fresh and frozen algae so that the particle size is less than about 8 mm, preferably about 0.5 mm to about 8 mm, more preferably about 2 to about 5 mm.

[0070] Algae can be shredded using equipment including, but not limited to, meat grinders, kitchen homogenizers, Polytron™ grinders, and any commercial cutter. Variations and adjustments to the shredding parameters are within the skill of those skilled in the art and depend only on the volume of the homogenate and the equipment used.

[0071] Fucoidan can be extracted from chopped algae using a suitable volume of aqueous solution. The volume of solution used can be increased without adversely affecting the recovery rate of the valuable component. Smaller volume solutions are preferred because they are easier to handle than larger volume solutions. Water can be purified by reverse osmosis and multiple filtrations (up to 0.1-micron membranes). Many aqueous solutions (e.g., saline solutions) can be used as alternatives to water. When considering the recovery of multiple water-soluble active ingredients, it is recommended to operate under near-neutral pH (5.0-8.0) and non-denaturing conditions to avoid degradation or denaturation of some active ingredients. For clarity, any extraction medium compatible with preserving the bioactive fucoidan component is within the scope of this application. Extraction is preferably carried out in pure water. Other preferred embodiments include those in which salt and / or a dissolving agent are added to the water before or during extraction.

[0072] Extraction can be carried out at about 60°C to 95°C, preferably about 80°C to 95°C. The extraction time is typically about 12 to about 24 hours, preferably about 10 to about 16 hours. The stirring speed and the volume of the aqueous solution can both affect the extraction time and yield.

[0073] The supernatant is then separated from the precipitate (solid / liquid separation). This separation can be performed quickly by filtration (using a sieve of approximately 50 micrometers), centrifugation, or using a commercial decanter. Variations and adjustments to the separation parameters are within the knowledge of those skilled in the art and depend only on the volume of the homogenate and the equipment used.

[0074] The resulting supernatant is then clarified to remove fine suspended matter that may affect process performance. The clarification process is carried out at a temperature of about 50°C to about 80°C, preferably at a temperature of about 40°C to about 60°C.

[0075] The clarified substance is then cooled to a temperature of about 15°C to about 30°C, preferably about 15°C to about 25°C.

[0076] The clarified product is then acidified at a pH of approximately 2 to precipitate proteins and alginate. For example, acidification can be carried out in the presence of sulfuric acid or hydrochloric acid, followed by clarification of the acidified product as described above, and finally neutralization of the solution.

[0077] The neutralized solution is then concentrated. This step can be performed by various methods, including but not limited to: dialysis, chromatography (adsorption, ion exchange, gel filtration), electrophoresis, ultrafiltration, partitioned density gradient ultracentrifugation, adsorption, and extraction.

[0078] In one specific embodiment, the solution can be ultrafiltered on a tangential flow filtration column at about 4°C to 25°C (although the temperature can be increased to about 40°C). The molecular weight cutoff of the column membrane is about 500 kDa, preferably 300 kDa, and most preferably 100 kDa. The obtained fraction is then dialyzed to obtain a first fractional extract, which comprises water-soluble fucoidan with an average molecular weight typically lower than the membrane cutoff, taking into account the inherent variations in membrane pore size and molecular conformation in the extraction solvent. This inherent variation applies to any membrane used herein. This fraction, hereinafter referred to as the natural fucoidan fraction, is naturally mineralized.

[0079] Molecular analysis of the fucoidan fraction showed that fucose constituted approximately 15-45% of the dry weight, and preferably 20-35%. Furthermore, 3-35% and more preferably 10-29% of the dry weight was composed of uronic acid. This fucoidan is rich in sulfate, as 12-30% and more preferably 15-25% of the dry weight is composed of sulfate (SO4) groups.

[0080] According to another embodiment, fucoidan can be extracted from chopped algae using an appropriate amount of aqueous solution in the presence of 1% calcium chloride. The extraction process is carried out at approximately 85°C for approximately 4 hours. This condition allows proteins containing alginate to precipitate. The resulting supernatant is collected, the polysaccharide is precipitated in the presence of ethanol, and then the fucoidan is further purified by ultrafiltration.

[0081] Depolymerized Fucoidan

[0082] Fucoidan can be used in its fully or partially depolymerized form. In one specific embodiment, the depolymerization of fucoidan is carried out by acid hydrolysis. The natural fucoidan is partially acidified to a pH of about 0.5 to about 2.0, preferably about 0.5 to about 1.0. The acidified solution is incubated at a temperature of about 55°C to about 70°C for about 4 hours. Depolymerization can be achieved by various methods, including but not limited to: ultrasonication, UV radiation, ozone decomposition, chemical, free radical, or enzymatic hydrolysis, and high-pressure, high-temperature hydrolysis.

[0083] The solution was then neutralized with NaOH, concentrated / purified by ultrafiltration, and subsequently dialyzed.

[0084] The fucoidan in the solution was then precipitated in the presence of ethanol, and the precipitate was dried. Variations and adjustments to the parameters for ethanol precipitation and drying are within the skill of those skilled in the art and depend only on the volume of the solution and the equipment used. The resulting fraction contains water-soluble fucoidan with an average molecular weight between about 5 kDa and about 25 kDa.

[0085] Demineralized Fucoidan

[0086] The fucoidan fraction can be further used, wholly or partially, in demineralized form. Demineralization can be carried out by industrial methods, such as, but not limited to, nanofiltration. Nanofiltration is a reverse osmosis process that uses a relatively open RO membrane, allowing water and small monovalent ions (Na+, K+, Cl-) to pass through. Variations and adjustments to nanofiltration parameters are within the grasp of those skilled in the art and depend only on the volume of the solution and the equipment used. This fraction is referred to as FHMW or FLMW, depending on whether the fucoidan fraction is natural or depolymerized.

[0087] Preparation of galactomannan

[0088] In one specific embodiment, the galactomannan of this application can be obtained from *Asparagus crassirhizoma* cultured according to patent application EP-0733636 A1. The culture technique of this patent is based on the principle of algal vegetative propagation and uses a special type of rope. Wild protoplasmic fragments are seeded on this unique rope and then proliferated through vegetative propagation / fission, significantly increasing biomass.

[0089] Fresh, frozen, or dried clean algae can be processed into fine powder. As described above, fresh and frozen algae are chopped to a particle size of less than about 8 mm, preferably about 0.5 mm to about 8 mm, and most preferably about 2 to 5 mm.

[0090] Natural galactomannan (i.e., naturally containing minerals)

[0091] Galactan is extracted from chopped algae using a suitable aqueous solution. The volume of solution used can be increased without adversely affecting the recovery rate of the active ingredient. Smaller solutions are preferred as they are easier to handle than larger aqueous solutions. The water can then be purified by reverse osmosis and multiple filtrations (down to 0.1 micrometer membranes). Many aqueous solutions (e.g., saline solutions) can be used instead of water. When considering the recovery of multiple water-soluble active ingredients, it is recommended to operate under near-neutral pH (6.0-8.0) and non-denaturing conditions to avoid degradation or denaturation of some active ingredients. For clarity, any extraction medium compatible with preserving the bioactive galactan components is within the scope of this application. Extraction is preferably carried out in pure water. Other preferred embodiments include those in which salt and / or a dissolving agent are added to the water before or during extraction.

[0092] Extraction can be carried out at about 50°C to 90°C, preferably about 60°C to about 80°C. Extraction time is typically about 1 to 8 hours, preferably about 4 to 6 hours. The stirring speed and the volume of the aqueous solution can both affect the extraction time and yield.

[0093] The supernatant is then separated from the precipitate (solid / liquid separation). This separation can be performed quickly by filtration (using a sieve of approximately 50 micrometers), centrifugation, or using a commercial decanter. Variations and adjustments to the separation parameters are within the knowledge of those skilled in the art and depend only on the volume of the homogenate and the equipment used.

[0094] The resulting supernatant is then clarified to remove fine suspended matter that may affect process performance. The clarification process is carried out at a temperature of about 50°C to about 70°C, preferably at about 60°C.

[0095] The clarified substance is then cooled to a temperature of about 30°C to about 50°C, preferably about 40°C.

[0096] The clarified product is then acidified at a pH of about 3 to about 5 (preferably about 4.5). For example, acidification can be carried out in the presence of sulfuric acid or hydrochloric acid, and then the acidified product is clarified according to the method described above.

[0097] The acidified substance is then decolorized by microfiltration and subsequently clarified as described above. Variations and adjustments to the microfiltration parameters are within the knowledge of those skilled in the art and depend only on the volume of the solution and the equipment used. The solution is then neutralized.

[0098] The depigmented solution is then concentrated. This step can be performed by various methods, including but not limited to dialysis, chromatography (adsorption, ion exchange, gel filtration), electrophoresis, ultrafiltration, partitioned density gradient ultracentrifugation, adsorption, and extraction.

[0099] In one specific embodiment, the solution can be ultrafiltered on a tangential flow filtration column at approximately 4°C–25°C (although the temperature can be increased to approximately 40°C). The molecular weight cutoff of the column membrane is approximately 10 kDa. The resulting fraction is then dialyzed to obtain a first extract comprising water-soluble galactans with an average molecular weight typically higher than the membrane cutoff, taking into account the inherent variations in membrane pore size and the molecular conformations in the extraction solvent, which are higher than the membrane cutoff.

[0100] The galactan in the solution is then precipitated in the presence of ethanol, and the precipitate is dried. Variations and adjustments to the parameters for ethanol precipitation and drying are within the skill of those skilled in the art and depend only on the volume of the solution and the equipment used. This galactan-rich fraction is hereinafter referred to as the mineralized galactan fraction.

[0101] Molecular analysis of the galactan fraction obtained from red algae showed that galactose constitutes about 15-95% of the dry weight of the galactan, preferably about 20-75%, and more preferably about 30-40%. Furthermore, 1-10% of the dry weight, and more preferably 1-5%, is composed of uronic acid. This galactan is rich in sulfate, as about 1-60% of its dry weight, and more preferably about 20-35%, is composed of sulfate (SO4) groups.

[0102] Estimation of polysaccharide molecular weight using HPSEC (High Performance Size Exclusion Chromatography)

[0103] The molecular weight of oligosaccharides formed by free radical depolymerization can be determined using a highly efficient size exclusion method. This method can be used to evaluate the number-average molecular weight (Mn), peak molecular weight (Mp), and polydispersity index (Ip) (=Mw / Mn) characterizing the homogeneity of the polysaccharide chains for each oligosaccharide. Calibration was obtained using pullulan standards (Nardella et al., 1996). Pullulan is a dextran, i.e., a neutral polysaccharide, while oligosaccharides from *Asparagus crassirhizoma* are highly sulfated. This is why the estimated mass of *Asparagus crassirhizoma* oligosaccharides can be similar to that of equivalent pullulan, but does not reflect the true mass of this oligosaccharide. This method is very useful for comparing the different fractions obtained from free radical depolymerization reactions carried out under different conditions. The protocol used is as described by Mulloy et al. (1997). Tandem TSK™ G3000 SW-XL and TSK™ G2000SW-XL columns were used. The eluent was a 0.1 M ammonium acetate solution, and the flow rate was 0.5 mL·min. -1 The refraction method was used for testing (refractive index monitor W, LDC, Analytical, Stone, Saffs., UK). Data processing was performed using software from the Church Stretton Polymer Laboratory in the UK.

[0104] According to a specific embodiment of this application, the galactan fraction was characterized by the method described above. According to this method, galactose comprised approximately 37% of the dry weight of the fraction, uronic acid comprised approximately 3% of the dry weight of the fraction, and sulfate comprised approximately 27% of the dry weight of the fraction. These galactans have an average molecular weight greater than approximately 100 kDa, and in a more specific embodiment, Mw is approximately 350 kDa (obtained from pullulan equivalents).

[0105] Depolymerization of galactomannan

[0106] Galactan can be used in its depolymerized form, either wholly or partially. In one specific embodiment, the depolymerization of galactan is carried out by acid hydrolysis. The natural galactan portion is acidified to a pH of about 0.5 to about 2.0, preferably about 0.5 to about 1.0. The acidification solution is incubated at a temperature of about 55°C to about 70°C for about 4 hours. Depolymerization can be achieved by various methods, including but not limited to: ultrasound, UV radiation, ozone decomposition, chemical, free radical or enzymatic hydrolysis, and high pressure and high temperature.

[0107] The solution was then neutralized, concentrated / purified by 2kDa ultrafiltration, and subsequently dialyzed.

[0108] The galactan in the solution is then precipitated in the presence of ethanol, and the precipitate is dried. Variations and adjustments to the parameters for ethanol precipitation and drying are within the skill of those skilled in the art and depend only on the volume of the solution and the equipment used. This portion is hereinafter referred to as the mineralized degraded galactan portion.

[0109] Demineralized galactomannan

[0110] The galactomannan portion can be further utilized, in whole or in part, in demineralized form. Demineralization can be carried out by industrial methods, such as, but not limited to, nanofiltration as described above.

[0111] Fucoidan: Galactan

[0112] According to other specific embodiments, the average molecular weight of galactan is greater than 100 kDa. According to other specific embodiments, the average molecular weight of galactan is about 350 kDa. According to other specific embodiments, the galactose content of galactan is about 37% of the dry weight of galactan. According to other specific embodiments, the uronic acid content of galactan is about 3% of the dry weight of galactan. According to other specific embodiments, the sulfate content of galactan is about 27% of the dry weight of galactan. According to other specific embodiments, the average molecular weight of fucoidan is about 0.1 kDa to about 100 kDa. According to other specific embodiments, the average molecular weight of fucoidan is about 5 kDa to about 25 kDa. According to other specific embodiments, the fucose content of fucoidan is about 20-35% of the dry weight of fucoidan. According to other specific embodiments, the uronic acid content of fucoidan is about 10-about 29% of the dry weight of fucoidan. According to other specific embodiments, the sulfate content of fucoidan is about 15-25% of the dry weight of fucoidan. According to other specific embodiments, the dry weight ratio of fucoidan to galactan in the composition is about 2.5:about 1 (w / w) to about 40:about 1 (w / w), or about 0.75:about 1 (w / w) to about 20:about 1 (w / w), or about 1:about 1 (w / w) to about 20:about 1 (w / w), or about 1:about 1 (w / w) to about 19:about 1 (w / w), or about 1:about 1 (w / w) to about 18:about 1 (w / w), or about 1:about 1 (w / w) to about 17:about 1 (w / w), or about 1:about 1 (w / w) to about 16:about 1 (w / w), or about 1:about 1 (w / w) to about 15:about 1 (w / w), or about 1:about 1 (w / w) to about 14:about 1 (w / w), or about 1: about 1 (w / w) to about 13.5: about 1 (w / w), or about 2: about 1 (w / w) to about 20: about 1 (w / w), or about 3: about 1 (w / w) to about 19: about 1 (w / w), or about 4: about 1 (w / w) to about 18: about 1 (w / w), or about 5: about 1 (w / w) to about 17: about 1 (w / w), or about 6: about 1 (w / w) to about 16: about 1 (w / w), or about 7: about 1 (w / w) to about 15: about 1 (w / w), or about 8: about 1 (w / w) to about 14: about 1 (w / w), or about 9: about 1 (w / w) to about 13.5: about 1 (w / w), or about 13.16: about 1 (w / w). According to other specific embodiments, the ratio of fucoidan to galactan in the composition is about 10 fucoidan: about 1 galactan (w / w). According to other specific embodiments, the galactan includes natural galactan. According to other specific embodiments, the fucoidan includes natural fucoidan. According to other specific embodiments, the fucoidan includes depolymerized fucoidan. According to other specific embodiments, the fucoidan includes demineralized fucoidan.According to other specific embodiments, the galactomannan includes demineralized galactomannan. According to other specific embodiments, the use is for external application.

[0113] Active ingredients and excipients

[0114] The composition of this application may further include, but is not limited to, at least one other active ingredient listed below, such as anesthetics, antiacne agents, anti-aging agents, antibacterial agents, anti-cellulite agents, antifungal agents, anti-inflammatory agents, anti-irritant agents, antioxidants, antiparasitic agents, anti-pollution agents, antiproliferative agents, antipruritics, anti-rosacea agents, anti-seborrheic agents, anti-stress agents, anti-telangiectatic agents, antiviral agents, anti-wrinkle agents, baby care products, bath and body care products, sedatives, cleansers, collagen synthesizers, elastase inhibitors, exfoliants, facial exfoliants, skin tightening agents, foot care products, free radical scavengers, immunomodulators, and keratolytic agents. The following are examples of skin care products: a skin-lifting agent, a makeup remover, a melanin-producing stimulant, a matrix metalloproteinase inhibitor, a moisturizer, an oil-absorbing agent, a penetration regulator, an anti-photoaging agent, a protective agent, a revitalizing agent, a regenerating agent, a reshaping agent, a sensitive skin agent, a shaving product agent, a skin defense enhancer, a skin tone purifier, a skin repair agent, a slimming agent, a smoothing agent, an emollient, a soothing agent, a sun care agent, a sun-free tanning agent, a firming agent, vitamin D, vitamin D analogs, corticosteroids, retinoids, calcineurin inhibitors, salicylic acid, coal tar, anthralin, methotrexate, ceramides, niacinamide, Abyssine™, Borealine™ Protect, Canadian Willowherb™, Neutrazen™, Tasmanian pepper, and whitening agents, or any other agent suitable for topical application of the cosmetic composition described herein, and which complements or enhances the effects of the fucoidan and galactan of this application. In one specific embodiment, the other active ingredients are antiproliferative agents, vitamin D, vitamin D analogs, corticosteroids, vitamin A-like substances, calcineurin inhibitors, salicylic acid, coal tar, or anthracene.

[0115] Agents capable of regulating cell differentiation or proliferation include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, these agents include retinoic acid and its derivatives (retinol, retinal, retinyl palmitate, trans-retinoic acid, 13-cis-retinoic acid, 9-cis-retinoic acid, retinoyl glucuronide, retinoic acid, isotretinoin, etratiate, acitretin, tazarotene, adapalene, β-carotene, retinyl esters), vitamin D and its derivatives (cholecalciferol, ergocalciferol, 25-hydroxycholecalciferol), growth factors, and estradiol derivatives.

[0116] Anesthetics include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, such agents include lidocaine hydrochloride and its derivatives.

[0117] Acne-fighting agents include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, these agents include benzoyl peroxide, retinoic acid and its derivatives (retinol, retinal, retinyl palmitate, trans-retinoic acid, 13-cis-retinoic acid, 9-cis-retinoic acid, retinoyl glucuronide, retinoic acid, isotretinoin, etratiate, acitretin, tazarotene, adapalene, β-carotene, retinyl esters), salicylic acid, sulfur, lime sulfide, ethanol, and acetone.

[0118] Anti-aging / anti-wrinkle agents include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, such agents include hyaluronic acid, sodium 2-pyrrolidone carboxylate, glycosaminoglycans, kinetin, retinoic acid and its derivatives (retinol, retinal, retinyl palmitate, trans-retinoic acid, 13-cis-retinoic acid, 9-cis-retinoic acid, retinoyl glucuronide, retinoic acid, isotretinoin, etratiate, acitretin, tazarotene, adapalene, β-carotene, retinyl esters), epidermal growth factor, ceramides, ethyl diiminomethyl guaiacol manganese chloride, glycation inhibitors, golden chamomile extract, and *Hydrocotyle vulgaris* extract.

[0119] Antimicrobial agents include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, these agents include eucalyptus extract, clindamycin phosphate, carvacrol, erythromycin, and tetracycline antibiotics.

[0120] Antifungal agents include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, these agents include econazole, ketoconazole, miconazole, amphotericin B, terbinafine, and piroctone olamine.

[0121] Anti-inflammatory agents include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, such agents include allantoin, vitamin E and its derivatives (α-tocopherol, δ-tocopherol, γ-tocopherol), chamomile oil, ginkgo oil, and tea extracts.

[0122] Anti-irritants / soothing agents / smoothing agents / sedatives include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, such agents include allantoin, tea extract, lavender oil, aloe vera, linden extract, willowherb extract, golden chamomile extract, kola nut extract, and Alternaria alterniflora fermentation extracts.

[0123] Antioxidants include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, these agents include furfuryladenine, panthenol, lipoic acid, coenzyme Q10, nicotinamide, melatonin, catalase, glutathione, superoxide dismutase, polyphenols, cysteine, allantoin, kinetin, vitamin C and its derivatives (ascorbate palmitate, magnesium ascorbate phosphate, sodium ascorbate phosphate), vitamin E and its derivatives (α-tocopherol, δ-tocopherol, γ-tocopherol), grape seed extract, and tea extract.

[0124] Antiproliferative agents include, but are not limited to, mitomycin C and methotrexate.

[0125] Antipruritic agents include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, such agents include thiabendazole, alimazine, and cyproheptadine.

[0126] Anti-rosacea agents / anti-capillary vasodilators include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, these agents include metronidazole, vasoconstrictors, benzoyl peroxide, azelaic acid, sulfur, soy protein, and glycosaminoglycans.

[0127] Anti-seborrhea agents include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, these agents include progesterone derivatives, isoleutrol, and juniperol.

[0128] Sensitive skin agents include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, these agents include rose oil and jasmine oil.

[0129] Cleaning agents include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, such agents include ammonium lauryl sulfate, ammonium lauryl ether sulfate, cocamide MEA, triethanolamine lauryl sulfate, sodium stearate, and nettle leaf extract.

[0130] Collagen synthesis agents include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, these agents include retinoic acid and its derivatives (retinol, retinal, retinyl palmitate, trans-retinoic acid, 13-cis-retinoic acid, 9-cis-retinoic acid, retinoyl glucuronide, retinoic acid, isotretinoin, etratiate, acitretin, tazarotene, adapalene, β-carotene, retinyl ester), vitamin C and its derivatives (ascorbate palmitate, magnesium ascorbate phosphate, sodium ascorbate phosphate), growth factors and their derivatives.

[0131] Exfoliating agents include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, these agents include α / β-hydroxy acids, salicylic acid, glycolic acid, lactic acid, citric acid, and walnut shell powder.

[0132] Facial exfoliants include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, these agents include glycolic acid, lactic acid, trichloroacetic acid, and phenol.

[0133] Skin-tightening agents / firming agents include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, these agents include dimethylaminoethanol, neurocosmetic active ingredients (similar to Botox™), chitosan, arnica extract, sweet fennel oil, and papaya extract.

[0134] Free radical scavengers / anti-pollution agents / anti-stress agents include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, these agents include grape seed extract, α-tocopherol and its esters, superoxide dismutase, certain metal chelating agents, vitamin C and its derivatives (ascorbate palmitate, magnesium ascorbate phosphate, sodium ascorbate phosphate).

[0135] Hair care products include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, such agents include poly-D-glucosamine, poly-N-acetyl-D-glucosamine, silachlor, and triethanolamine lauryl sulfate.

[0136] Matrix metalloproteinase inhibitors include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, such agents include tea extracts, polyphenols, *Spatholobus suberectus* extract, *Euonymus alatus* extract, *Notopterygium incisum* extract, quercetin, glycosaminoglycans, polymethoxyflavonoids, N-acetylcysteine, 2-furanyldioxime, isoflavones, vitamin C and its derivatives (ascorbate palmitate, ascorbate magnesium phosphate, ascorbate sodium phosphate), retinoic acid and its derivatives (retinol, retinaldehyde, retinyl palmitate, trans-retinoic acid, 13-cis-retinoic acid, 9-cis-retinoic acid, retinoyl glucuronide, retinoic acid, isotretinoin, etratiate, acitretin, tazarotene, adapalene, β-carotene, retinyl esters), and isohydroxyoxime derivatives.

[0137] Moisturizers include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, such agents include cucumber extract, sodium 2-pyrrolidone carboxylate, sodium PCA, sodium hyaluronate, chitosan and its derivatives, α-hydroxy acids, hyaluronic acid, and hydrolyzed wheat protein.

[0138] Osmotic conditioners include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, these agents include mannitol, galactitol, and betaine.

[0139] Protectants include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, such agents include poly-N-acetyl-D-glucosamine, poly-D-glucosamine, alkylamides, chitosan, golden chamomile extract, tea extract, and Alternaria alternata fermentation extract.

[0140] Revitalizing agents include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, such agents include rosemary extract, rosewood extract, geranium extract, and vitamin E and its derivatives (α-tocopherol, δ-tocopherol, γ-tocopherol).

[0141] Skin repair agents include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, these agents include retinoic acid and its derivatives (retinol, retinal, retinyl palmitate, trans-retinoic acid, 13-cis-retinoic acid, 9-cis-retinoic acid, retinoyl glucuronide, retinoic acid, isotretinoin, etratiate, acitretin, tazarotene, adapalene, beta-carotene, retinyl esters), allantoin, eucalyptus extract, lavender oil, rose oil, and activators of collagen synthesis and skin extracellular matrix components.

[0142] Slimming agents / anti-cellulite agents include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, these agents include golden chamomile extract, dihydromyricetin, theobromine, theophylline, aminophylline, caffeine, isoproterenol hydrochloride, epinephrine, α-MSH agonists, adenylate cyclase activators, and phosphodiesterase inhibitors.

[0143] Sun care products / photoaging agents include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, these reagents include PABA (p-aminobenzoic acid) and its derivatives, gluconolactone, salicylates, cinnamates, benzophenone, dibenzoylmethane, oxybenzone, vitamin E and its derivatives (α-tocopherol, δ-tocopherol, γ-tocopherol), ethyl diiminomethyl guaiacol manganese chloride, glycosaminoglycans, retinoic acid and its derivatives (retinol, retinaldehyde, retinyl palmitate, trans-retinoic acid, 13-cis-retinoic acid, 9-cis-retinoic acid, retinoyl glucuronide, retinoic acid, isotretinoin, etratiate, acitretin, tazarotene, adapalene, β-carotene, retinyl esters), titanium dioxide, octyl methoxycinnamate, benzophenone, octyl salicylate, willowherb extract, western sorrel extract, golden chamomile extract, tea extract, and Alternaria alternifolia fermentation extract.

[0144] Sunscreens / melanin production stimulants include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, these agents include dihydroxyacetone, α-MSH agonists, adenylate cyclase activators, and phosphodiesterase inhibitors.

[0145] Skin toners include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, these agents include nettle extract, orange blossom extract, rosewood extract, and witch hazel extract.

[0146] Whitening agents / pigmenting agents include, but are not limited to, plant extracts, algae extracts, fruit extracts, vegetable extracts, legume extracts, ferments, protein hydrolysates, peptides, yeast extracts and their derivatives, microbial extracts, animal-derived extracts, and synthetic compounds. More specifically, these reagents include arbutin, azelaic acid, vitamin C and its derivatives (ascorbate palmitate, ascorbate magnesium phosphate, ascorbate sodium phosphate), hydroquinone, N-acetyl-4-S-cysteylphenol, kojic acid, melanin inhibitor (nonapeptide), retinoic acid, retinoic acid and its derivatives (retinol, retinaldehyde, retinyl palmitate, trans-retinoic acid, 13-cis-retinoic acid, 9-cis-retinoic acid, retinoyl glucuronide, retinoic acid, etrati ester, etrati ester, acitretin, tazarotene, adapalene, β-carotene, retinyl ester), western sorrel extract, licorice, mulberry, bearberry (arctostaphylos uva-ursi, bearberry), tyrosinase inhibitors, melanosome transport inhibitors, and melanin scavengers.

[0147] The compositions of this application may also include other excipients, such as buffers, carriers, chelating agents, conditioning agents, colorants, detackifiers, emollients, emulsifiers, film-forming agents, foaming agents, humectants, lactoyl lactate esters, lipophilic agents, lubricants, neutralizers, oils, opacifiers, preservatives, solubilizers, solvents, stabilizers, surfactants, thickeners, viscous agents, desiccant and wetting agents.

[0148] Buffers are salts of bases / acids that are compatible with the properties of the skin and its pH. Sodium acetate is a common example of a buffer, but it is not the only one.

[0149] Carriers are components that can assist in the application of active ingredients. Isohexadecane is a commonly used example of a carrier, but it is not limited to this.

[0150] Chelating agents are components that can bind to monovalent and divalent cations, such as tetrasodium EDTA and disodium EDTA, but are not limited to these.

[0151] Conditioners are ingredients that have lubricating and moisturizing effects, such as cetyltrimethylammonium chloride, diceryldimethylammonium chloride, tridecyl polyether-l2, quaternary ammonium salt-z7, quaternary ammonium salt-l8, polyquaternary ammonium salt-10, behenyltrimethylmethylammonium sulfate, cetearyl alcohol, stearamide propyl dimethylamine, trimethylsilyldimethylsiloxane, isolaryl alcohol polyether-6, octyl styrene polyol-4, polydimethylsiloxane, polydimethylsiloxane alcohol, cyclopentasiloxane, alkanol polyether-7, alkanol polyether-9, linoleic acid, and glycerol, but not limited to these.

[0152] Detackifiers are components that can adsorb onto sticky materials and reduce their tendency to adhere, such as, but not limited to, cyclopentamethoxysiloxane, polydimethylsiloxane, vinyl polydimethylsiloxane, phenyltrimethylpolysiloxane, isopropyl esters, isostearates, dimethyl sebacate and dipropyl sebacate.

[0153] Emollients are ingredients that have lubricating and moisturizing effects, such as isopropyl palmitate, sunflower seed oil, mineral oil, stearyl stearate, isopropyl myristate, lanolin, caprylic / capric triglyceride, cyclopentamethoxysiloxane, polydimethylsiloxane, vinyl polydimethylsiloxane, diphenylpropyl polydimethylsiloxane, alkyl polydimethylsiloxane, sorbitan stearate, sucrose distearate, myristyl alcohol, myristyl lactate, cetyl acetate, dioctyl ether, Floraester-20, maleated soybean oil, cyclopentamethoxysiloxane, shea butter, hydrogenated coconut oil, isopropyl palmitate, diisostearoyl trimethylolpropanesilyl alkyl silicate, and alkyl benzoate, but not limited to these.

[0154] Emulsifiers are ingredients that prevent the separation of incompatible substances in an emulsion, help to uniformly disperse one substance into another, and improve texture, uniformity, consistency, and stability. Examples include cetearyl alcohol, glyceryl stearate, alkyl acrylate crosspolymers, stearic acid, emulsifying waxes, sorbitan oleate, sorbitan stearate, polysorbate, sorbitol, polyethylene glycol polysorbate, triethanolamine, cyclopentamethoxysiloxane, polydimethylsiloxane copolyol, PEG-30 dihydroxystearate, sucrose distearate, PEG-100 stearate, sodium dioctyl sulfosuccinate, polyacrylamide, isoparaffins, lauryl ether-7, cetyl phosphate, DEA cetyl phosphate, ethylene glycol stearate, stearyl alcohol, cetyl alcohol, behenyltrimethylmethyl methyl ammonium sulfate, and cetearyl alcohol polyether-2, but are not limited to these.

[0155] Film-forming agents are components that can form dimensionally stable and continuous films to minimize formulation stickiness, such as wheat protein, eicosene copolymer, perfluoromethyl isopropyl ether, diisostearoyltrimethylolpropane siloxane silicate, polydimethylsiloxane, vinyl polydimethylsiloxane, and cyclopentadimethylsiloxane, but not limited to these.

[0156] Foaming agents are ingredients that can adjust the air content in a product, such as lauramide DEA and cocoamide MEA, disodium lauryl ether sulfosuccinate, disodium N-octadecyl sulfosuccinate, ammonium lauryl sulfate, triethanolamine lauryl sulfate, sodium lauryl sulfate, and sodium 2-ethylhexyl sulfate, but not limited to these.

[0157] Moisturizers are ingredients that can maintain a constant humidity level and lock in moisture, such as glycerol, PEG-8, butylene glycol, and propylene glycol, but are not limited to these.

[0158] Lubricants are components that can increase lubricity and reduce friction to improve coating, such as, but not limited to, polydimethylsiloxane and polydimethylsiloxane copolyol.

[0159] Neutralizing agents are components that can alter acid-base balance, such as triethanolamine and sodium hydroxide, but are not limited to these.

[0160] Opacifiers are ingredients that can make transparent or translucent products more creamy or pearlescent, such as glyceryl stearate and PEG-100 stearate, but not limited to these.

[0161] Preservatives are ingredients that can delay or prevent microbial or chemical deterioration and discoloration, such as, but not limited to, at least one of the following: glycerol, phenylpropanol (e.g., A-Leen™ Aroma-3), glyceryl caprylate (e.g., Dermosoft™ GMCY MB or Softisan™ GC8 Palm free); capryloyl oxime acid (and) caprylyl glycol (and) glycerol (e.g., Spectrastat™ G2 Natural MB), water (and) glycerol (and) sodium levulinate (and) sodium anisinate (e.g., Dermosoft™ 1388 ECO NAL); potassium sorbate; and sodium benzoate; or any combination thereof. In a specific embodiment, the preservative is a combination of glycerol with at least one of phenylpropanol and glyceryl caprylate (Dermosoft™ GMCY MB or Softisan™ GC8 Palm free). In a specific embodiment, the preservative is glycerol, with a concentration of about 3% to about 90% w / w, or 3% to 15%, or 3% to 20%, or 3% to 25%, or 3% to 30%, or 3% to 35%, or 3% to 40%, or 3% to 45%, or 3% to 50%, or 3% to 55%, or 3% to 60%, or 3% to 65%, or 3% to 70%, or 3% to 75%, or 3% to 85%, or about 3%, or about 18%, or about 73%, or about 74%.In a specific embodiment, the preservative is glycerol at a concentration of about 3% to about 90% and another preservative selected from one or more of the following: glyceryl caprylate (e.g., Dermosoft™ GMCY MB or Softisan™ GC8 Palm free), water (and) glycerol (and) sodium levulinate (and) sodium anisinate (e.g., Dermosoft™ 1388 ECO NAL), potassium sorbate, and sodium benzoate, each preservative in a concentration of about 0.01% to about 10%, or about 0.1% to about 10%, or about 0.05% to about 10%, or about 0.06% to about 10%, or about 0.07% to about 10%, or about 0.08% to about 10%, or about 0.09% to about 10%, or about 0.1% to about 10%, or about 0.1% to about 8%, or about 0.1% to about 7%, or about 0.1% to about 6%, or about 0.1% to about 5%, or about 0.1% to about 4%, or about 0.1%. From about 3%, or about 0.1% to about 2%, or about 0.1% to about 1%, or about 0.1% to about 0.9%, or about 0.1% to about 0.8%, or about 0.1% to about 0.7%, or about 0.1% to about 0.6%, or about 0.1% to about 0.5%, or about 0.1% to about 0.4%, or about 0.1% to about 0.3%, or about 0.1% to about 0.2%, or about 0.2% to about 10%, or about 0.2% to about 8%, or about 0.2% to about 7%, or about 0.2% to about 6%, or about 0.2% to about 5%. Or about 0.2% to about 4%, or about 0.2% to about 3%, or about 0.2% to about 2%, or about 0.2% to about 1%, or about 0.2% to about 0.9%, or about 0.2% to about 0.8%, or about 0.2% to about 0.7%, or about 0.2% to about 0.6%, or about 0.2% to about 0.5%, or about 0.2% to about 0.4%, or about 0.2% to about 0.3%, or about 0.3% to about 10%, or about 0.3% to about 8%, or about 0.3% to about 7%, or about 0.3% to about 6%, or about 0.3%. % to about 5%, or about 0.3% to about 4%, or about 0.3% to about 3%, or about 0.3% to about 2%, or about 0.3% to about 1%, or about 0.3% to about 0.9%, or about 0.3% to about 0.8%, or about 0.3% to about 0.7%, or about 0.3% to about 0.6%, or about 0.3% to about 0.5%, or about 0.3% to about 0.4%, or about 0.4% to about 10%, or about 0.1% to about 5%, or about 0.1% to about 4%, or about 0.1% to about 3%, or about 0.1% to about 2.5%.

[0162] Solubilizers are components that enable incompatible components to become part of a homogeneous solution, such as sorbitol, polysorbate, cetearyl alcohol polyether, stearyl alcohol polyether, and PEG, but not limited to these.

[0163] Stabilizers are components that maintain physical and chemical properties during and after processing, and prevent or limit changes in the physical properties of substances throughout the product's life cycle. Examples include, but are not limited to, polyethylene, sodium chloride, stearyl alcohol, xanthan gum, tetrasodium EDTA, and polydimethylsiloxane copolyol.

[0164] Surfactants are components that, when dissolved in water or an aqueous solution, can reduce surface tension, reduce interfacial tension between two liquids or between a liquid and a solid. Examples include, but are not limited to, sodium dioctyl sulfosuccinate, octyl phenyl ether-40, isolaryl ether-6, ammonium lauryl sulfate, lauryl alcohol, lauramide DEA, and cocamidopropyl betaine.

[0165] Thickeners are ingredients that can absorb water to impart viscosity, improve viscosity or texture, and stabilize emulsions, such as stearic acid, magnesium aluminum silicate, carbomer, alkyl acrylate crosspolymers, polyacrylamide, isoparaffins, lauryl ether-7, cetyl alcohol, xanthan gum, alkyl polydimethylsiloxane, hydroxyethyl cellulose, glyceryl stearate, pentaerythritol tetrastearate, stearyl alcohol, and polyquaternium-10, but not limited to these.

[0166] Viscosities are components that can control the fluidity and internal flow resistance of a fluid, such as magnesium aluminum silicate, octyl glycol, and myristol, but not limited to these.

[0167] Desiccant is an ingredient that can absorb moisture from a product to maintain humidity, such as, but not limited to, carboxyvinyl polymers, acrylic copolymers, polyacrylamide, polysaccharides, natural gums, clay, modified clay, metal salts, and fatty acids.

[0168] Wetting agents are components that can reduce the surface tension of water and improve its penetration or spreading properties on a surface, such as caprylate, caprylyl glycol, glyceryl decanoate, polyglycerol-2-decanoate, but not limited to these.

[0169] The compositions of this application can be formulated to provide a specific, controllable delivery system. Non-limiting examples of such delivery systems include: sustained-release systems, immediate-release systems, instant-release systems, delayed-release systems, zero-release systems, and dual- or multi-rate drug delivery systems. Such controllable delivery systems can be achieved through specific formulations, including: chemical delivery systems, multiple emulsions, microemulsions, nanoemulsions, encapsulations (such as liposomes, microspheres, nanospheres, microsponges, microbeads, and cyclodextrins), polymer matrices, polymer cosmetic conjugates, oil bodies / oil proteins, oil-soluble molecular membranes, skin patches, and single-dose formulations.

[0170] The compositions of this application can be formulated into cosmetically acceptable carriers, including: solutions, dispersions, emulsions, serums, microparticle dispersions, vesicular ionic or nonionic dispersions, alcohol or hydroalcohol solutions, creams, gels, water-in-oil or oil-in-water emulsions, foams, aerosols, solids, or pastes.

[0171] The applications of the compositions of this application include topical cosmetic compositions. Non-limiting examples of such topical compositions include: skin creams, cleansing creams, skin lotions, skin gels, skin foams, sun care compositions, makeup remover creams, makeup remover lotions, foundation creams, liquid foundations, bath and shower products, deodorant compositions, antiperspirant compositions, shaving product compositions, aftershave gels or lotions, beauty aid compositions, depilatory creams, soap compositions, hand sanitizer compositions, cleansing soaps, baby care products, hair care products, shampoos, styling lotions, conditioning lotions, hair waxes, hair gels, hair coloring compositions, reshaping compositions, permanent hair loss prevention compositions, or any other compositions suitable for topical cosmetic solutions.

[0172] Subjects

[0173] As used herein, the term "subject" or "subject in need" refers to a subject who will benefit from receiving an effective amount of the composition of this application. It refers to animals, mammals, and in this particular embodiment, humans. In this particular embodiment, the subject has sensitive skin. The compositions of this application may also be used for preclinical purposes in other animals.

[0174] The terms “a,” “one,” and “the,” as well as similar pronouns, used herein should be interpreted as encompassing both the singular and plural forms, unless otherwise stated herein or clearly provided by the context.

[0175] The terms “including,” “having,” “containing,” and “comprising” should be interpreted as open-ended terms (i.e., meaning “including but not limited to”) unless otherwise stated.

[0176] The numerical ranges listed in this document are for brief reference only, and unless otherwise stated, each individual value is included in the specification as if listed separately in this document. Numerical values ​​for all subsets of this range are also included in the specification as if listed separately in this document.

[0177] All methods described herein may be performed in any suitable order unless otherwise stated or the context clearly specifies otherwise.

[0178] The term "about" has its usual meaning. In embodiments, it may refer to ±10% of the represented value.

[0179] Any and all examples or exemplary language (such as "for example") provided herein are intended only to better illustrate this application and, unless otherwise stated, do not constitute a limitation on the scope of this application.

[0180] Nothing in the specification should be construed as indicating that any unclaimed element is necessary for the implementation of this application.

[0181] This application will be further illustrated by the following non-limiting examples.

[0182] Example 1 :Materials and methods

[0183] Preparation process of fucoidan for 1% and 2% Aldavine™ 5X Formaldehyde pretreatment (polyphenol capture); Water extraction; Solid / liquid separation; Particulate removal; Alginate precipitation and removal; filter; Depolymerization is achieved through chemical hydrolysis; and Dehydration and homogenization of powder particle size (atomization).

[0184] The generated fucoidan has a medium molecular weight (MMW) of 20,000-50,000 Da, and is named "fucoidan powder" in this paper.

[0185] Preparation process of galactomannans for 1% and 2% Aldavine™ 5X Water extraction; Solid / liquid separation; Particulate removal; filter; Demineralization was performed to prepare an aqueous galactomannan extract; Prepare galactomannan syrup.

[0186] Table 3 below lists the composition of the galactomannan syrup used in each formulation A1 to A19. [Table 3]: Galactan Syrup Formulations

[0187] Aldavine™ 5X

[0188] Aldavine™ 5X Manufacturing Process

[0189] The composition / formulation comprises fucoidan powder and galactomannan syrup in a ratio of 1:2.5, water, one or more preservatives, and optionally sorbitol, and is prepared according to the following method.

[0190] The 1% w / w Aldavine™ 5X formulation contains 0.025% w / w fucoidan powder and 0.0625% w / w galactan syrup (3% solids, i.e., 1.9 mg / g solids). The 2% w / w Aldavine™ 5X formulation contains 0.05% w / w fucoidan powder and 0.125% w / w galactan syrup. These compositions were used for the analyses described in Examples 2 through 10.

[0191] Table 4 below lists the composition of each formulation A1 to A19. [Table 4]: Aldavine™ 5X Formulation a: Galactomannan syrup G2; b: Galactomannan syrup G3; c: Galactomannan syrup G4; d: Galactomannan syrup G1; e: Galactomannan syrup G5; f: Galactomannan syrup G6; g: Galactomannan syrup G7; h: Galactomannan syrup G8; and i: Galactomannan syrup G9.

[0192] Preparation of Aldavine™ 5X-A1 formulation

[0193] The purified water is heated to 60 + / - 3°C in the heated master tank equipped with a propeller agitator.

[0194] Add Dermosoft™ GMCY MB and stir at 60+ / -3°C for 5 minutes or until completely dissolved.

[0195] Add galactomannan syrup G2 (see Table 3) and stir for 5 minutes at 60 + / - 3°C.

[0196] Add fucoidan slowly while stirring rapidly. Stir vigorously at 60 ± 3°C for at least 30 minutes or until completely dissolved.

[0197] Add sorbitol powder while stirring vigorously. Stir at 60 ± 3°C for at least 2 hours or until the solution is homogeneous.

[0198] Test the pH value (specification: 5.5-6.5). If it exceeds this specification, adjust with 1N HCl or 2% NaOH and stir for another 15 minutes.

[0199] Use a 40-mesh or 60-mesh sieve to filter the product.

[0200] Preparation of Aldavine™ 5X-A2 formulation

[0201] The purified water is heated to 60 + / - 3°C in the heated master tank equipped with a propeller agitator.

[0202] Add Spectrastat™ G2 Natural MB and stir at 60+ / -3°C for 5 minutes or until completely dissolved.

[0203] Add galactomannan syrup G3 (see Table 3) and stir for 5 minutes at 60 + / - 3°C.

[0204] Add fucoidan slowly while stirring rapidly. Stir vigorously at 60 ± 3°C for at least 30 minutes or until completely dissolved.

[0205] Add sorbitol powder while stirring vigorously. Stir at 60 ± 3°C for at least 2 hours or until the solution is homogeneous.

[0206] Test the pH value (specification: 5.5-6.5). If it exceeds this specification, adjust with 1N HCl or 2% NaOH and stir for another 15 minutes.

[0207] Use a 40-mesh or 60-mesh sieve to filter the product.

[0208] Preparation of Aldavine™ 5X-A3 formulation

[0209] The purified water is heated to 60 + / - 3°C in the heated master tank equipped with a propeller agitator.

[0210] Add Spectrastat™ G2 Natural MB and stir at 60+ / -3°C for 5 minutes or until completely dissolved.

[0211] Add galactomannan syrup G4 (see Table 3) and stir for 5 minutes at 60 + / - 3°C.

[0212] Add fucoidan slowly while stirring rapidly. Stir vigorously at 60 ± 3°C for at least 30 minutes or until completely dissolved.

[0213] Add sorbitol powder while stirring vigorously. Stir at 60 ± 3°C for at least 2 hours or until the solution is homogeneous.

[0214] Test the pH value (specification: 5.5-6.5). If it exceeds this specification, adjust with 1N HCl or 2% NaOH and stir for another 15 minutes.

[0215] Use a 40-mesh or 60-mesh sieve to filter the product.

[0216] Preparation of Aldavine™ 5X-A4 formulation

[0217] The purified water is heated to 60 + / - 3°C in the heated master tank equipped with a propeller agitator.

[0218] Add glycerol and stir for 5 minutes at 60 + / - 3°C.

[0219] Add galactomannan syrup G1 (see Table 3) and stir for 5 minutes at 60 + / - 3°C.

[0220] Add fucoidan slowly while stirring rapidly. Stir vigorously at 60 ± 3°C for at least 30 minutes or until completely dissolved.

[0221] Add sorbitol powder while stirring vigorously. Stir at 60 ± 3°C for at least 2 hours or until the solution is homogeneous.

[0222] Test the pH value (specification: 5.5-6.5). If it exceeds this specification, adjust with 1N HCl or 2% NaOH and stir for another 15 minutes.

[0223] Use a 40-mesh or 60-mesh sieve to filter the product.

[0224] Preparation of Aldavine™ 5X-A5, A7 and A8 formulations

[0225] The purified water is heated to 60 + / - 3°C in the heated master tank equipped with a propeller agitator.

[0226] Add glycerol and stir at 60 ± 3°C for 5 minutes. Add galactomannan syrup (G1 for A5, G2 for A7, G4 for A8, (see Table 3)) and stir at 60 ± 3°C for 5 minutes.

[0227] Add fucoidan slowly while stirring rapidly. Stir vigorously at 60 ± 3°C for at least 30 minutes or until completely dissolved.

[0228] Test the pH value (specification: 5.5-6.5). If it exceeds this specification, adjust with 1N HCl or 2% NaOH and stir for another 15 minutes.

[0229] Use a 40-mesh or 60-mesh sieve to filter the product.

[0230] Preparation of Aldavine™ 5X-A6 formulation

[0231] The purified water is heated to 60 + / - 3°C in the heated master tank equipped with a propeller agitator.

[0232] Add phenoxyethanol and stir at 60 + / - 3°C for 5 minutes or until completely dissolved.

[0233] Add potassium sorbate and stir for 5 minutes at 60 + / - 3°C.

[0234] Add galactomannan syrup G5 (see Table 3) and stir for 5 minutes at 60 + / - 3°C.

[0235] Add fucoidan slowly while stirring rapidly. Stir vigorously at 60 ± 3°C for at least 30 minutes or until completely dissolved.

[0236] Add sorbitol powder while stirring vigorously. Stir at 60 ± 3°C for at least 2 hours or until the solution is homogeneous.

[0237] Test the pH value (specification: 5.5-6.5). If it exceeds this specification, adjust with 1N HCl or 2% NaOH and stir for another 15 minutes.

[0238] Use a 40-mesh or 60-mesh sieve to filter the product.

[0239] Preparation of Aldavine™ 5X-A9 formulation

[0240] Stir the glycerol and heat to 60 + / - 3°C.

[0241] Add Dermosoft™ GMCY MB and stir at 60+ / -3°C for 5 minutes or until completely dissolved.

[0242] Add sorbitol powder while stirring vigorously. Stir at 60 ± 3°C for at least 30 minutes or until the solution is homogeneous.

[0243] Add purified water and stir at 60+ / -3°C for 5 minutes or until the solution is homogeneous.

[0244] Add galactomannan syrup G2 (see Table 3) and stir at 60 + / - 3°C for 5 minutes or until the solution is homogeneous.

[0245] Add fucoidan slowly while stirring rapidly. Stir vigorously at 60 ± 3°C for at least 30 minutes or until completely dissolved.

[0246] Test the pH value (specification: 5.5-6.5). If it exceeds this specification, adjust with 1N HCl or 2% NaOH and stir for another 15 minutes.

[0247] Use a 40-mesh or 60-mesh sieve to filter the product.

[0248] Preparation of Aldavine™ 5X-A10 formulation

[0249] The purified water is heated to 60 + / - 3°C in the heated master tank equipped with a propeller agitator.

[0250] Add potassium sorbate and stir for 5 minutes at 60 + / - 3°C.

[0251] Add sodium benzoate and stir for 5 minutes at 60 + / - 3°C.

[0252] Add galactomannan syrup G6 (see Table 3) and stir for 5 minutes at 60 + / - 3°C.

[0253] Add fucoidan slowly while stirring rapidly. Stir vigorously at 60 ± 3°C for at least 30 minutes or until completely dissolved.

[0254] Add sorbitol powder while stirring vigorously. Stir at 60 ± 3°C for at least 2 hours or until the solution is homogeneous.

[0255] Test the pH value (specification: 5.5-6.5). If it exceeds this specification, adjust with 1N HCl or 2% NaOH and stir for another 15 minutes.

[0256] Use a 40-mesh or 60-mesh sieve to filter the product.

[0257] Preparation of Aldavine™ 5X-A11 formulation

[0258] The purified water is heated to 60 + / - 3°C in the heated master tank equipped with a propeller agitator.

[0259] Add Dermosoft™ 1388 ECO NAL and stir for 5 minutes at 60+ / -3°C.

[0260] Add galactomannan syrup G7 (see Table 3) and stir for 5 minutes at 60 + / - 3°C.

[0261] Add fucoidan slowly while stirring rapidly. Stir vigorously at 60 ± 3°C for at least 30 minutes or until completely dissolved.

[0262] Add sorbitol powder while stirring vigorously. Stir at 60 ± 3°C for at least 2 hours or until the solution is homogeneous.

[0263] Test the pH value (specification: 5.5-6.5). If it exceeds this specification, adjust with 1N HCl or 2% NaOH and stir for another 15 minutes.

[0264] Use a 40-mesh or 60-mesh sieve to filter the product.

[0265] Preparation of Aldavine™ 5X-A12 formulation

[0266] The purified water is heated to 60 + / - 3°C in the heated master tank equipped with a propeller agitator.

[0267] Add sodium benzoate and stir at 60 + / - 3°C for 5 minutes or until completely dissolved.

[0268] Add potassium sorbate and stir at 60 + / - 3°C for 5 minutes or until completely dissolved.

[0269] Add galactomannan syrup G6 (see Table 3) and stir for 5 minutes at 60 + / - 3°C.

[0270] Add fucoidan slowly while stirring rapidly. Stir vigorously at 60 ± 3°C for at least 30 minutes or until completely dissolved.

[0271] Add sorbitol powder while stirring vigorously. Stir at 60 ± 3°C for at least 2 hours or until the solution is homogeneous.

[0272] Test the pH value (specification: 5.5-5.9). If it exceeds this specification, adjust with 1N HCl or 2% NaOH and stir for another 15 minutes.

[0273] Use a 40-mesh or 60-mesh sieve to filter the product.

[0274] Preparation of Aldavine™ 5X-A13 formulation

[0275] The purified water is heated to 60 + / - 3°C in the heated master tank equipped with a propeller agitator.

[0276] Add Dermosoft™ 1388 ECO NAL and stir at 60+ / -3°C for 5 minutes or until completely dissolved.

[0277] Add galactomannan syrup G7 (see Table 3) and stir for 5 minutes at 60 + / - 3°C.

[0278] Add fucoidan slowly while stirring rapidly. Stir vigorously at 60 ± 3°C for at least 30 minutes or until completely dissolved.

[0279] Add sorbitol powder while stirring vigorously. Stir at 60 ± 3°C for at least 2 hours or until the solution is homogeneous.

[0280] Test the pH value (specification: 5.5-5.9). If it exceeds this specification, adjust with 1N HCl or 2% NaOH and stir for another 15 minutes.

[0281] Use a 40-mesh or 60-mesh sieve to filter the product.

[0282] Preparation of Aldavine™ 5X-A14 formulation

[0283] Stir the glycerol and heat to 60 + / - 3°C.

[0284] Add Softisan™ GC8 Palm Free and stir at 60+ / -3°C for 5 minutes or until completely dissolved.

[0285] Add sorbitol powder while stirring vigorously. Stir at 60 ± 3°C for at least 30 minutes or until the solution is homogeneous.

[0286] Add purified water and stir at 60+ / -3°C for 5 minutes or until the solution is homogeneous.

[0287] Add galactomannan syrup G8 (see Table 3) and stir at 60 + / - 3°C for 5 minutes or until the solution is homogeneous.

[0288] Add fucoidan slowly while stirring rapidly. Stir vigorously at 60 ± 3°C for at least 30 minutes or until completely dissolved.

[0289] Test the pH value (specification: 5.5-6.5). If it exceeds this specification, adjust with 1N HCl or 2% NaOH and stir for another 15 minutes.

[0290] Use a 40-mesh or 60-mesh sieve to filter the product.

[0291] Preparation of Aldavine™ 5X-A15 formulation

[0292] The purified water is heated to 60 + / - 3°C in the heated master tank equipped with a propeller agitator.

[0293] Add A-Leen™ Aroma-3 and stir at 60+ / -3°C for 5 minutes or until completely dissolved.

[0294] Add galactomannan syrup G9 (see Table 3) and stir for 5 minutes at 60 + / - 3°C.

[0295] Add fucoidan slowly while stirring rapidly. Stir vigorously at 60 ± 3°C for at least 30 minutes or until completely dissolved.

[0296] Add sorbitol powder while stirring vigorously. Stir at 60 ± 3°C for at least 2 hours or until the solution is homogeneous.

[0297] Test the pH value (specification: 5.5-6.5). If it exceeds this specification, adjust with 1N HCl or 2% NaOH and stir for another 15 minutes.

[0298] Use a 40-mesh or 60-mesh sieve to filter the product.

[0299] Preparation of Aldavine™ 5X-A16 formulation

[0300] The purified water is heated to 60 + / - 3°C in the heated master tank equipped with a propeller agitator.

[0301] Add Dermosoft™ 1388 ECO NAL and stir at 60 + / - 3°C for 5 minutes or until completely dissolved.

[0302] Add galactomannan syrup G7 (see Table 3) and stir for 5 minutes at 60 + / - 3°C.

[0303] Add fucoidan slowly while stirring rapidly. Stir vigorously at 60 ± 3°C for at least 30 minutes or until completely dissolved.

[0304] Add sorbitol powder while stirring vigorously. Stir at 60 ± 3°C for at least 2 hours or until the solution is homogeneous.

[0305] Test the pH value (specification: 5.5-6.5). If it exceeds this specification, adjust with 1N HCl or 2% NaOH and stir for another 15 minutes.

[0306] Use a 40-mesh or 60-mesh sieve to filter the product.

[0307] Preparation of Aldavine™ 5X-A17 formulation

[0308] The purified water is heated to 60 + / - 3°C in the heated master tank equipped with a propeller agitator.

[0309] Add Dermosoft™ 1388 ECO NAL and stir at 60+ / -3°C for 5 minutes or until completely dissolved.

[0310] Add galactomannan syrup G7 (see Table 3) and stir for 5 minutes at 60 + / - 3°C.

[0311] Add fucoidan slowly while stirring rapidly. Stir vigorously at 60 ± 3°C for at least 30 minutes or until completely dissolved.

[0312] Add glycerol while stirring vigorously. Stir at 60 ± 3°C for at least 2 hours or until the solution is homogeneous.

[0313] Test the pH value (specification: 5.5-6.5). If it exceeds this specification, adjust with 1N HCl or 2% NaOH and stir for another 15 minutes.

[0314] Use a 40-mesh or 60-mesh sieve to filter the product.

[0315] Preparation of Aldavine™ 5X-A18 formulation

[0316] The purified water is heated to 60 + / - 3°C in the heated master tank equipped with a propeller agitator.

[0317] Add Dermosoft™ 1388 ECO NAL and stir at 60+ / -3°C for 5 minutes or until completely dissolved.

[0318] Add galactomannan syrup G7 (see Table 3) and stir for 5 minutes at 60 + / - 3°C.

[0319] Add fucoidan slowly while stirring rapidly. Stir vigorously at 60 ± 3°C for at least 30 minutes or until completely dissolved.

[0320] Add glycerol while stirring vigorously. Stir at 60 ± 3°C for at least 2 hours or until the solution is homogeneous.

[0321] Test the pH value (specification: 5.5-6.5). If it exceeds this specification, adjust with 1N HCl or 2% NaOH and stir for another 15 minutes.

[0322] Use a 40-mesh or 60-mesh sieve to filter the product.

[0323] Preparation of Aldavine™ 5X-A19 formulation

[0324] The purified water is heated to 60 + / - 3°C in the heated master tank equipped with a propeller agitator.

[0325] Add A-Leen™ Aroma-3 and stir at 60+ / -3°C for 5 minutes or until completely dissolved.

[0326] Add galactomannan syrup G9 (see Table 3) and stir for 5 minutes at 60 + / - 3°C.

[0327] Add fucoidan slowly while stirring rapidly. Stir vigorously at 60 ± 3°C for at least 30 minutes or until completely dissolved.

[0328] Add glycerol while stirring vigorously. Stir at 60 ± 3°C for at least 2 hours or until the solution is homogeneous.

[0329] Test the pH value (specification: 5.5-6.5). If it exceeds this specification, adjust with 1N HCl or 2% NaOH and stir for another 15 minutes.

[0330] Use a 40-mesh or 60-mesh sieve to filter the product.

[0331] Sensitive skin replacement model

[0332] For sensitive skin, substitutes are prepared using skin cells (fibroblasts and keratinocytes) extracted from patient biopsy tissue (male or female, Caucasian, aged 36-65 years).

[0333] The extracted fibroblasts were cultured in DMEM medium supplemented with 10% fetal bovine serum (Hyclone), 100 U / ml penicillin G (Sigma), and 25 µg / mL gentamicin (Shering) at 37°C, 5% CO2, and 95% humidity.

[0334] The extracted keratinocytes were placed in a 3:1 mixture of DMEM and Ham's F12 (Gibco) medium supplemented with 5% fetal bovine serum II (Hyclone), 10 ng / mL epidermal growth factor (EGF) (Austral Biologicals), 100 U / mL penicillin G (Sigma), 25 µg / mL gentamicin (Schering), 5 µg / mL insulin (Sigma Aldrich), 0.4 µg / mL hydrocortisone (Calbiochem), and 10 -10 M cholera toxin (MPBiomedicals) was cultured at 37°C, 5% CO2, and 95% humidity.

[0335] After extracting and proliferating different skin cell types (fibroblasts and keratinocytes), skin substitutes were reconstructed. Briefly, after 28 days of culture, fibroblasts were seeded into 6-well plates and treated with ascorbic acid (50 µg / mL) to promote collagen production and allow the two cell layers to overlap, forming a surface equivalent to the dermis. Keratinocytes were then seeded onto this dermal surface to form the epidermis. After one week of culture, the substitutes were moved to the air-liquid interface to promote keratinocyte differentiation and obtain different epidermal layers. After 11 days, the substitutes were continuously treated in the medium for 10 days every 3 days with Aldavine™ 5X (1%, 2%) or methotrexate (used as a positive control at a concentration of 734 µM). After treatment, the culture of the substitutes was stopped, and analysis was performed.

[0336] Histological staining

[0337] Masson's trichrome staining method was used to distinguish the different layers of skin (i.e., stratum corneum, epidermis, and dermis). Skin substitutes were fixed in formalin and embedded in paraffin. Masson's trichrome staining was then performed on 5 μm sections. This staining was performed by a series of sequential immersions in different reagents: toluene, Wiegert hematoxylin, water, fuchsin-ponceau, phosphomolybdic acid, ethanol, and aniline blue. Epidermal thickness was measured under each condition and analyzed using ImageJ™ software. Each condition was analyzed three times.

[0338] Immunofluorescence

[0339] Skin biopsy tissue was placed in the optimal cutting temperature (OCT) and then cut into 5 μm sections. The sections were fixed with acetone at -20°C for 10 minutes and then rinsed. Slides were incubated with primary antibody diluted in 1% PBS-bovine serum albumin (BSA) solution for 45 minutes (room temperature) or overnight at 4°C in the dark. For Wnt5a, cells were permeabilized with Triton™ X100 solution before staining. The primary antibodies used were anti-K14 antibody (Cederlane), anti-Ki67 antibody (Abcam), anti-Wnt5a antibody (Biolegend), and anti-Wnt5a antibody (Invitrogen). After rinsing, slides were incubated with secondary antibody in the dark for 20 minutes. After incubation, the slides were rinsed three times before mounting with DAPI Fluoromount-G™ (SouthernBiotech). Images were captured using a confocal microscope (LSM 900 with Airscan 2, Carl Zeiss) or a fluorescence microscope (Zeiss Axiolmager M2), and the fluorescence intensity was quantitatively analyzed using ImageJ™ software.

[0340] Western blot

[0341] Skin tissue was collected and lysed using a Vibrogrinder cryo-soaker at -80°C. The total protein obtained was then lysed with RIPA lysis buffer supplemented with protease inhibitors. Cell lysates were then centrifuged to remove cell debris, and the clarified supernatant was used for Western blotting analysis. Proteins were mixed with Laemmli buffer, separated by SDS-PAGE, and then transferred to a PVDF membrane. The membrane was blocked for 1 hour at room temperature with Tris-buffered saline (TBS)-0.05% Tween™ 20 (TBS-T) solution containing 5% skim milk powder, and then incubated overnight at 4°C with anti-Clasp2 primary antibody (Santa Cruz). The next day, the membrane was incubated for 1 hour at room temperature with HRP-conjugated anti-rabbit IgG secondary antibody. The immunoreaction was visualized by enhanced chemiluminescence detection (ECL, Cytiva), and data were acquired and analyzed using ImageJ™ software.

[0342] Challenge Test

[0343] The efficacy of each antimicrobial preservative was tested according to Chapter 5.1.3 of the 11th edition of the European Pharmacopoeia.

[0344] Statistical analysis

[0345] All data were analyzed using GraphPad™ Prism 9 software. Each experiment was repeated at least three times, and data are presented as mean ± standard error of mean. All obtained data and percentage changes were subjected to one-way ANOVA, followed by post-hoc tests for each analysis. A p-value < 0.05 was considered statistically significant. p<0.05, p<0.01, p<0.001).

[0346] Example 2: The effect of Aldavine™ 5X treatment on epidermal thickness

[0347] Aldavine™ 5X at concentrations of 1% and 2% was applied to the skin substitute, and the epidermal thickness was measured as described in Example 1.

[0348] like Figure 1 As shown, 1% and 2% concentrations of Aldavine™ 5X significantly reduced epidermal thickness by 33% and 40%, respectively. This reduction in epidermal thickness indicates decreased skin cell proliferation. The obtained data were subjected to one-way ANOVA, followed by the Kruskal-Wallis test.

[0349] Example 3: Effects of Aldavine™ 5X treatment on Ki67 expression

[0350] Aldavine™ 5X at concentrations of 1% and 2% was applied to skin substitutes, and Ki67 expression (used as a proliferation marker) was measured as described in Example 1.

[0351] like Figure 2 As shown, 1% and 2% concentrations of Aldavine™ 5X significantly reduced Ki67 expression by 55% and 63%, respectively. This reduction in Ki67 expression indicates decreased skin cell proliferation. The obtained data were subjected to one-way ANOVA, followed by the Kruskal-Wallis test.

[0352] Example 4: Effects of Aldavine™ 5X treatment on K14 expression

[0353] Aldavine™ 5X at concentrations of 1% and 2% was applied to skin substitutes, and the expression of K14 (used as a proliferation marker) was measured as described in Example 1.

[0354] like Figure 3As shown, 1% Aldavine™ 5X significantly reduced K14 expression by 19%. This reduction in K14 expression indicates decreased skin cell proliferation. The obtained data were subjected to one-way ANOVA and corrected for Dunnett's error.

[0355] Example 5: Effects of Aldavine™ 5X treatment on CLASP2 expression

[0356] Aldavine™ 5X at concentrations of 1% and 2% was applied to skin substitutes, and the expression of Clasp2 (used as a marker of skin cell proliferation and migration) was measured as described in Example 1.

[0357] like Figure 4 As shown, 1% and 2% concentrations of Aldavine™ 5X significantly reduced Clasp2 expression by 44% and 86%, respectively. This reduction in Clasp2 expression indicates a decrease in skin cell proliferation and migration. The obtained data were subjected to one-way ANOVA, followed by the Kruskal-Wallis test.

[0358] Example 6: Effects of Aldavine™ 5X treatment on Wnt5a expression

[0359] Aldavine™ 5X at concentrations of 1% and 2% was applied to skin substitutes, and the expression of Wnt5a (used as a marker of skin cell proliferation and migration) was measured as described in Example 1.

[0360] like Figure 5 As shown, 1% and 2% concentrations of Aldavine™ 5X significantly reduced Wnt5a expression by 17% and 22%, respectively. This reduction in Wnt5a expression indicates a decrease in skin cell proliferation and migration. The obtained data were subjected to one-way ANOVA and corrected for Brown-Forsythe.

[0361] Example 7: Effects on Differentiation -- Effects of Aldavine™ 5X Treatment on Pterygosyllabuse Protein Expression

[0362] Aldavine™ 5X at concentrations of 1% and 2% was applied to skin substitutes, and the expression of scutellarin (used as a marker of skin cell differentiation) was measured as described in Example 1.

[0363] Aldavine™ 5X at concentrations of 1% and 2% significantly increased the expression of scutellarin by 40% and 152%, respectively. This restoration of scutellarin expression indicates normal skin cell differentiation. The obtained data were subjected to one-way ANOVA followed by the Kruskal-Wallis test.

[0364] Example 8: Challenge Test

[0365] The efficacy of each antimicrobial preservative was tested according to the method described in Example 1. The microorganisms used were: Gram-positive Staphylococcus aureus ATCC 6538, Gram-negative Pseudomonas aeruginosa ATCC 9027 and Escherichia coli ATCC 8739, yeast Candida albicans ATCC 10231 and mold Aspergillus brasiliensis ATCC 16404.

[0366] Example 9: Stability testing – UV spectroscopy and sensory properties

[0367] The formulations and galactomannan syrups submitted for sensory stability testing were divided into three groups of samples. One group was stored at 4°C, another at 25°C, and the last at 50°C. These three groups of samples were monitored at different time points: T0, 15 days (D15), 1 month (1M), 3 months (3M), and 6 months (6M). Parameters at each time point were monitored by a qualified technician to examine the maintenance of various characteristics over time. Monitored parameters included odor, visual aspects (color, turbidity, precipitation), and UV spectrum. These parameters must remain stable for at least three months or longer relative to the T0 time point and compared to samples stored at 4°C to be considered stable. The test was terminated at the initial time point when the formulation or galactomannan syrup exhibited instability in at least one of the above sensory characteristics.

[0368] Example 10: Effects of different preservatives on formulation performance

[0369] Table 5 below summarizes the challenge test and stability results for formulations A1-A19. Table 5 also lists the stability data for specific galactomannan syrups used in some formulations (see Table 3 above). [Table 5] Stability Results The scope of the claims should not be limited to the embodiments described in the examples, but should be given the broadest interpretation consistent with the whole specification.

[0370] References

[0371] Dubois M, Gilles KA, Hamilton JK, Rebers PA, Smith F, Colorimetric determination of carbohydrates and related substances, Anal Chem 1956; 28(3):350-6.

[0372] Blumenkrantz N, Asboe-Hansen G, A novel method for the quantitative determination of uronic acid, Anal Biochem 1973; 54(2):484-9, [PubMed: 4269305] Nardella A, Chaubet F, Boisson-Vidal C, Blondin C.

[0373] Durand P, Jozefonvicz J, Low molecular weight fucoidan for anticoagulation prepared from high molecular weight fucoidan extracted from Euglena bufota by free radical method and ion exchange chromatography, Carbohydr Res 1996; 289:201-8, [PubMed: 8805780].

[0374] Mulloy B, Gee C, Wheeler SF, Wait R, Gray E, Barrowcliffe TW, Determination of molecular weight of low molecular weight heparin by gel permeation chromatography, Thromb Haemost 1997; 77(4):668-74, [PubMed:9134640].

Claims

1. Use of a topical composition comprising fucoidan and galactomannan in a dry weight ratio of about 0.75: about 1 w / w to about 20: about 1 w / w, water, a first preservative comprising at least 3% w / w glycerol, and a second preservative comprising phenylpropanol; said topical composition being used to reduce epidermal thickness and / or inhibit skin cell proliferation in a subject with such need.

2. The use according to claim 1, wherein the composition comprises fucoidan and galactan in a dry weight ratio of about 12:about 1 w / w to about 18:about 1 w / w.

3. The use according to claim 1 or 2, wherein the fucoidan is extracted from brown algae, and / or the galactan is extracted from red algae.

4. The use according to any one of claims 1-3, wherein the fucoidan is extracted from *Bombyx mori*, and / or the galactan is extracted from *Asparagus chinensis*.

5. The use according to any one of claims 1-4, wherein the second preservative is composed of phenylpropanol.

6. The use according to any one of claims 1-5, wherein the second preservative consists of about 0.2-0.4% w / w phenylpropanol.

7. The use according to any one of claims 1-6, wherein the first preservative comprises or consists of about 14% w / w to about 65% w / w glycerol.

8. The use according to any one of claims 1-7, wherein the first preservative comprises or is composed of: Glycerol of about 20% w / w to about 60% w / w, or about 30% w / w to about 60% w / w, or about 40% w / w to about 60% w / w, or about 45% w / w to about 55% w / w, or about 50% w / w to about 53% w / w.

9. A stable topical composition comprising fucoidan and galactan in a dry weight ratio of about 0.75: about 1 w / w to about 20: about 1 w / w, water, a first preservative comprising about 14% w / w to about 65% w / w glycerol, and a second preservative comprising about 0.2-0.4% w / w phenylpropanol.

10. The composition according to claim 9, comprising fucoidan and galactan in a dry weight ratio of about 12:about 1 w / w to about 18:about 1 w / w.

11. The composition according to claim 9 or 10, wherein the fucoidan is extracted from brown algae, and / or the galactan is extracted from red algae.

12. The composition according to any one of claims 9-11, wherein the fucoidan is extracted from *Bombyx mori*, and / or the galactan is extracted from *Asparagus chinensis*.

13. The composition according to any one of claims 9-12, wherein the second preservative is composed of phenylpropanol.

14. The composition according to any one of claims 9-12, wherein the second preservative consists of about 0.2-0.4% w / w phenylpropanol.

15. The composition according to any one of claims 9-14, wherein the first preservative comprises or is composed of: Glycerol of about 20% w / w to about 60% w / w, or about 30% w / w to about 60% w / w, or about 40% w / w to about 60% w / w, or about 45% w / w to about 55% w / w, or about 50% w / w to about 53% w / w.

Citation Information

Patent Citations

  • Extraction of organic silicon compounds with biological activity from algae

    EP0733636A1